Since joining Bioventus as CEO in April 2020, Ken Reali has overseen two $500 million acquisitions.
Six things to know:
1. Mr. Reali succeeded Tony Bihl after Mr. Bihl retired April 20, 2020.
2. Mr. Reali is optimistic about the company's 2021 performance, he said in a second quarter earnings call.
"We continue to expect measured improvements in the operating environment as we move through 2021, fueled primarily by the increase in availability of vaccines and an increasing percentage of vaccinated Americans, as well as Canadians and Europeans, and we continue to expect a return to normalized year-over-year growth trends in the third quarter of 2021," he said.
3. Mr. Reali said in a May 31 interview with Triangle Business Journal that the pandemic didn't affect their plans when setting up the $45 million acquisition of Bioness.
"2020 taught all of us that the core principles of doing business remain the same," he told the publication. "It is the approach that needs to be flexible and safe to ensure success. Set your strategy and follow it through. In most cases though, face-to-face discussions are still paramount to relationship building and completing important transactions."
4. Mr. Reali has more than 28 years of experience in the medical device industry. He previously had executive roles at Biomet, Stryker and Smith+Nephew.
5. He received his bachelor's degree in business administration at Valparaiso (Ind.) University.
6. Mr. Reali serves on the boards of Ossio Integrative Orthopedics, AdvaMed and Dysis Medical.